Research programme: anti-IGF monoclonal antibodies - Shin Nippon Biomedical LaboratoriesAlternative Names: m610.27; m67; m708.5
Latest Information Update: 17 Oct 2014
At a glance
- Originator National Cancer Institute (USA); Shin Nippon Biomedical Laboratories
- Class Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action Insulin-like growth factor I inhibitors; Insulin-like growth factor II inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 14 Oct 2014 Preclinical trials in Cancer in USA (unspecified route)